Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

G Attard; J Clark; L Ambroisine; I G Mills; G Fisher; P Flohr; A Reid; S Edwards; G Kovacs; D Berney; C Foster; C E Massie; A Fletcher; J S De Bono; P Scardino; J Cuzick; C S Cooper; Transatlantic Prostate Group

doi:10.1038/sj.bjc.6604472

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

G Attard
, J Clark
, L Ambroisine
, I G Mills
, G Fisher
, P Flohr
, A Reid
, S Edwards
, G Kovacs
, D Berney
, C Foster
, C E Massie
, A Fletcher
, J S De Bono
, P Scardino
, J Cuzick
, C S Cooper
, Transatlantic Prostate Group

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

92 Citations (Scopus)

Abstract

A fluorescence in situ hybridisation (FISH) assay has been used to screen for ETV1 gene rearrangements in a cohort of 429 prostate cancers from patients who had been diagnosed by trans-urethral resection of the prostate. The presence of ETV1 gene alterations (found in 23 cases, 5.4%) was correlated with higher Gleason Score (P=0.001), PSA level at diagnosis (P=<0.0001) and clinical stage (P=0.017) but was not linked to poorer survival. We found that the six previously characterised translocation partners of ETV1 only accounted for 34% of ETV1 re-arrangements (eight out of 23) in this series, with fusion to the androgen-repressed gene C15orf21 representing the commonest event (four out of 23). In 5'-RACE experiments on RNA extracted from formalin-fixed tissue we identified the androgen-upregulated gene ACSL3 as a new 5'-translocation partner of ETV1. These studies report a novel fusion partner for ETV1 and highlight the considerable heterogeneity of ETV1 gene rearrangements in human prostate cancer.

Original language	English
Pages (from-to)	314-20
Number of pages	7
Journal	British Journal of Cancer
Volume	99
Issue number	2
DOIs	https://doi.org/10.1038/sj.bjc.6604472
Publication status	Published - 22 Jul 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Coenzyme A Ligases
Cohort Studies
DNA-Binding Proteins
Gene Fusion
Gene Rearrangement
Genetic Heterogeneity
Humans
In Situ Hybridization, Fluorescence
Male
Paraffin Embedding
Prostatic Neoplasms
Reverse Transcriptase Polymerase Chain Reaction
Transcription Factors
Translocation, Genetic

Access to Document

10.1038/sj.bjc.6604472

Cite this

Attard, G., Clark, J., Ambroisine, L., Mills, I. G., Fisher, G., Flohr, P., Reid, A., Edwards, S., Kovacs, G., Berney, D., Foster, C., Massie, C. E., Fletcher, A., De Bono, J. S., Scardino, P., Cuzick, J., Cooper, C. S., & Transatlantic Prostate Group (2008). Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. British Journal of Cancer, 99(2), 314-20. https://doi.org/10.1038/sj.bjc.6604472

@article{f760e3b2f1344de992e5d789727c34be,

title = "Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer",

abstract = "A fluorescence in situ hybridisation (FISH) assay has been used to screen for ETV1 gene rearrangements in a cohort of 429 prostate cancers from patients who had been diagnosed by trans-urethral resection of the prostate. The presence of ETV1 gene alterations (found in 23 cases, 5.4\%) was correlated with higher Gleason Score (P=0.001), PSA level at diagnosis (P=<0.0001) and clinical stage (P=0.017) but was not linked to poorer survival. We found that the six previously characterised translocation partners of ETV1 only accounted for 34\% of ETV1 re-arrangements (eight out of 23) in this series, with fusion to the androgen-repressed gene C15orf21 representing the commonest event (four out of 23). In 5'-RACE experiments on RNA extracted from formalin-fixed tissue we identified the androgen-upregulated gene ACSL3 as a new 5'-translocation partner of ETV1. These studies report a novel fusion partner for ETV1 and highlight the considerable heterogeneity of ETV1 gene rearrangements in human prostate cancer.",

keywords = "Coenzyme A Ligases, Cohort Studies, DNA-Binding Proteins, Gene Fusion, Gene Rearrangement, Genetic Heterogeneity, Humans, In Situ Hybridization, Fluorescence, Male, Paraffin Embedding, Prostatic Neoplasms, Reverse Transcriptase Polymerase Chain Reaction, Transcription Factors, Translocation, Genetic",

author = "G Attard and J Clark and L Ambroisine and Mills, \{I G\} and G Fisher and P Flohr and A Reid and S Edwards and G Kovacs and D Berney and C Foster and Massie, \{C E\} and A Fletcher and \{De Bono\}, \{J S\} and P Scardino and J Cuzick and Cooper, \{C S\} and \{Transatlantic Prostate Group\}",

year = "2008",

month = jul,

day = "22",

doi = "10.1038/sj.bjc.6604472",

language = "English",

volume = "99",

pages = "314--20",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "2",

}

Attard, G, Clark, J, Ambroisine, L, Mills, IG, Fisher, G, Flohr, P, Reid, A, Edwards, S, Kovacs, G, Berney, D, Foster, C, Massie, CE, Fletcher, A, De Bono, JS, Scardino, P, Cuzick, J, Cooper, CS & Transatlantic Prostate Group 2008, 'Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer', British Journal of Cancer, vol. 99, no. 2, pp. 314-20. https://doi.org/10.1038/sj.bjc.6604472

TY - JOUR

T1 - Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

AU - Attard, G

AU - Clark, J

AU - Ambroisine, L

AU - Mills, I G

AU - Fisher, G

AU - Flohr, P

AU - Reid, A

AU - Edwards, S

AU - Kovacs, G

AU - Berney, D

AU - Foster, C

AU - Massie, C E

AU - Fletcher, A

AU - De Bono, J S

AU - Scardino, P

AU - Cuzick, J

AU - Cooper, C S

AU - Transatlantic Prostate Group

PY - 2008/7/22

Y1 - 2008/7/22

N2 - A fluorescence in situ hybridisation (FISH) assay has been used to screen for ETV1 gene rearrangements in a cohort of 429 prostate cancers from patients who had been diagnosed by trans-urethral resection of the prostate. The presence of ETV1 gene alterations (found in 23 cases, 5.4%) was correlated with higher Gleason Score (P=0.001), PSA level at diagnosis (P=<0.0001) and clinical stage (P=0.017) but was not linked to poorer survival. We found that the six previously characterised translocation partners of ETV1 only accounted for 34% of ETV1 re-arrangements (eight out of 23) in this series, with fusion to the androgen-repressed gene C15orf21 representing the commonest event (four out of 23). In 5'-RACE experiments on RNA extracted from formalin-fixed tissue we identified the androgen-upregulated gene ACSL3 as a new 5'-translocation partner of ETV1. These studies report a novel fusion partner for ETV1 and highlight the considerable heterogeneity of ETV1 gene rearrangements in human prostate cancer.

AB - A fluorescence in situ hybridisation (FISH) assay has been used to screen for ETV1 gene rearrangements in a cohort of 429 prostate cancers from patients who had been diagnosed by trans-urethral resection of the prostate. The presence of ETV1 gene alterations (found in 23 cases, 5.4%) was correlated with higher Gleason Score (P=0.001), PSA level at diagnosis (P=<0.0001) and clinical stage (P=0.017) but was not linked to poorer survival. We found that the six previously characterised translocation partners of ETV1 only accounted for 34% of ETV1 re-arrangements (eight out of 23) in this series, with fusion to the androgen-repressed gene C15orf21 representing the commonest event (four out of 23). In 5'-RACE experiments on RNA extracted from formalin-fixed tissue we identified the androgen-upregulated gene ACSL3 as a new 5'-translocation partner of ETV1. These studies report a novel fusion partner for ETV1 and highlight the considerable heterogeneity of ETV1 gene rearrangements in human prostate cancer.

KW - Coenzyme A Ligases

KW - Cohort Studies

KW - DNA-Binding Proteins

KW - Gene Fusion

KW - Gene Rearrangement

KW - Genetic Heterogeneity

KW - Humans

KW - In Situ Hybridization, Fluorescence

KW - Male

KW - Paraffin Embedding

KW - Prostatic Neoplasms

KW - Reverse Transcriptase Polymerase Chain Reaction

KW - Transcription Factors

KW - Translocation, Genetic

U2 - 10.1038/sj.bjc.6604472

DO - 10.1038/sj.bjc.6604472

M3 - Article

C2 - 18594527

SN - 0007-0920

VL - 99

SP - 314

EP - 320

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 2

ER -

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this